Access to hematopoietic stem cell transplant for patients with sickle cell anemia

Emily Riehm Meier, Theodore Johnson, Kerice Pinkney, Maria C. Velez, Naynesh Kamani, Isaac Odame

Research output: Contribution to journalReview article

2 Scopus citations


Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with phenotypically severe sickle cell anemia, and survival rates following matched-sibling HSCT are very high. However, despite cure rates much higher than HSCT for malignant diseases, the field has been slow to adopt this treatment modality for sickle cell anemia. This article explores some of the social forces that may contribute to this dichotomy.

Original languageEnglish (US)
Article numbere27105
JournalPediatric Blood and Cancer
Issue number9
StatePublished - Sep 2018



  • diversity
  • healthcare disparities
  • hematopoietic stem cell transplant
  • hydroxyurea
  • sickle cell anemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this